GlaxoSmithKline (NYSE:GSK) Earns Neutral Rating from Citigroup

Share on StockTwits

Citigroup reaffirmed their neutral rating on shares of GlaxoSmithKline (NYSE:GSK) in a research report released on Wednesday, Stock Target Advisor reports.

A number of other research firms also recently issued reports on GSK. Deutsche Bank reiterated a hold rating on shares of GlaxoSmithKline in a report on Thursday, October 31st. New Street Research raised GlaxoSmithKline from a reduce rating to a hold rating in a research report on Wednesday, October 16th. Jefferies Financial Group reissued a buy rating on shares of GlaxoSmithKline in a research report on Thursday, August 29th. UBS Group reissued a neutral rating on shares of GlaxoSmithKline in a research report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. reissued a neutral rating on shares of GlaxoSmithKline in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $41.79.

NYSE:GSK opened at $44.42 on Wednesday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 0.56 and a current ratio of 0.82. The company has a market cap of $110.42 billion, a PE ratio of 14.06, a PEG ratio of 3.03 and a beta of 0.70. GlaxoSmithKline has a 52-week low of $36.41 and a 52-week high of $46.01. The stock has a 50-day simple moving average of $42.96 and a 200 day simple moving average of $41.12.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, October 30th. The pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.10. The business had revenue of $11.57 billion during the quarter, compared to the consensus estimate of $11.34 billion. GlaxoSmithKline had a return on equity of 92.73% and a net margin of 13.76%. On average, research analysts predict that GlaxoSmithKline will post 3.08 earnings per share for the current fiscal year.

In related news, Director Plc Glaxosmithkline purchased 177,777 shares of GlaxoSmithKline stock in a transaction that occurred on Tuesday, September 10th. The stock was purchased at an average cost of $45.00 per share, with a total value of $7,999,965.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prime Capital Investment Advisors LLC acquired a new stake in shares of GlaxoSmithKline in the third quarter valued at approximately $26,000. Prestige Wealth Management Group LLC acquired a new stake in shares of GlaxoSmithKline in the second quarter valued at approximately $26,000. Berman Capital Advisors LLC lifted its position in shares of GlaxoSmithKline by 58.1% in the second quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the last quarter. Financial Gravity Wealth Inc. lifted its position in shares of GlaxoSmithKline by 62.7% in the second quarter. Financial Gravity Wealth Inc. now owns 799 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 308 shares during the last quarter. Finally, Manchester Financial Inc. acquired a new stake in shares of GlaxoSmithKline in the second quarter valued at approximately $39,000. 11.19% of the stock is owned by institutional investors.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: Is it better to buy a fund with a higher or lower NAV?

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.